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Enhancing immune responses with immune-modulatory
monoclonal antibodies (mAbs) directed to inhibitory
immune-receptors is a promising modality in cancer
therapy. Clinical efficacy has been demonstrated with anti-
bodies blocking inhibitory immune checkpoints such as
CTLA-4 or PD-1/PD-L1. Treatment with Ipilimumab
(Yervoy®), a fully human CTLA-4 specific mAb, showed
durable clinical efficacy and improved overall survival in
metastatic melanoma; its mechanism(s) of action, however,
are only partially understood. Recent studies in melanoma
mouse models revealed that the anti-tumor activity of
CTLA-4 blockade is mediated by FcgRIV-expressing
macrophages in the tumor microenvironment (TME) via
in-trans depletion of tumor-infiltrating regulatory T cells
(Tregs). We speculated that a similar mechanism might
operate in melanoma patients responding to Ipilimumab.
To investigate this hypothesis, we interrogated peripheral
blood mononuclear cells (PBMCs) and matched mela-
noma metastases from 15 patients responding (R) and 14
non-responding (NR) to Ipilimumab. Our findings show,
for the first time, that Ipilimumab leads to the depletion
in vitroof Tregs via an antibody-dependent-cellular-
cytotoxicity (ADCC) mechanism, selectively mediated by
FcgRIIIA (CD16)-expressing, nonclassical monocytes
(CD14+CD16++). In contrast, classical CD14++CD16-
monocytes, lacking the FcgRIIIA expression, are unable to
deplete Tregs in an ADCC assay. Interestingly, patients
responding to Ipilimumab displayed significantly higher
baseline peripheral frequencies of nonclassical monocytes
than nonresponder patients. Evaluation of matched
melanoma metastases from pre- and post-Ipilimumab
time-points by IHC revealed that, in the TME, responders
had the highest CD68+/CD163+ macrophage ratios at
baseline, and showed decreased infiltration of Tregs after
treatment. Notably, baseline Treg infiltration was compar-
able between the two groups. Our findings provide novel
mechanistic insight into the clinical activity of Ipilimumab,
highlighting the contribution of host-dependent factors
into the final outcome of antibody-based immune-
modulatory therapies and identify nonclassical mono-
cytes as a potential biomarker of response.
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